# US 10,869,750 B2 · Endovascular stent grafts and methods of using said stent grafts > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,750 B2 - Document ID: US10869750B2 - Status: Granted - Kind: B2 - Application number: 16/126,246 - Filed: 2018-09-10 - Published: 2020-03-12 - Granted: 2020-12-22 - Earliest claimed: 2018-09-10 - Assignees: Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen - Applicants: Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen - Inventors: Andreas Greiner; Stefan Jockenhövel; Andrij Pich; Larissa Hussmann; Valentine Gesché - Web page: https://patentgrep.com/patent/US10869750B2 ## CPC - A61B 17/12118: {for positioning in conjunction with a stent} - A61F 2/07: Stent-grafts - A61B 17/11: for performing anastomosis; Buttons for anastomosis - A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)} - A61L 27/52: Hydrogels or hydrocolloids - A61L 27/56: Porous materials, {e.g. foams or sponges} - A61L 31/048: {obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence)} - A61L 31/145: {Hydrogels or hydrocolloids} - A61L 31/146: {Porous materials, e.g. foams or sponges} - A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} - D04B 21/205: {Elongated tubular articles of small diameter, e.g. coverings or reinforcements for cables or hoses} - A61B 17/1219: {expandable in contact with liquids} - A61B 2017/00898: {expandable upon contact with fluid} - A61B 2017/1107: {for blood vessels} - A61F 2/86: Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure - A61F 2/90: characterised by a net-like or mesh-like structure - A61F 2/91: made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes - A61F 2002/061: {provided with means for allowing access to secondary lumens} - A61F 2002/065: {Y-shaped blood vessels} - A61F 2002/077: {having means to fill the space between stent-graft and aneurysm wall, e.g. a sleeve} - A61F 2210/0076: multilayered, e.g. laminated structures - A61F 2250/001: for adjusting a diameter - A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body - A61L 2300/414: Growth factors - A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons - A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices - D10B 2403/0122: Smooth surfaces, e.g. laminated or coated - D10B 2509/06: Vascular grafts; stents - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - D04B: KNITTING - D10B: INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES ## Abstract AN endovascular stent graft including a hydrogel capable of retarded swelling when coming into contact with blood upon implantation in a patient is provided. Methods for the treatment of aneurysms and the prevention of ischemic neurological damage, in particular spinal cord damage, in patients receiving aneurysm repair procedures, using said endovascular stent grafts is also provided. ## Claims ### Claim 1 An endovascular stent graft comprising an area having one or more through holes coated at least partially with a hydrogel capable of retarded reduction of the diameter of or retarded occlusion of said through holes by swelling upon implantation in a subject, wherein the retarded reduction or retarded occlusion occurs over a time course of one to four weeks. ### Claim 2 (depends on 1) The endovascular stent graft of claim 1, wherein said area having one or more through holes is a porous membrane. ### Claim 3 (depends on 1) The endovascular stent graft of claim 1, wherein said area having one or more through holes is a textile porous membrane. ### Claim 4 (depends on 3) The endovascular stent graft of claim 3, wherein said textile porous membrane is a warp knitted textile mesh structure. ### Claim 5 (depends on 2) The endovascular stent graft of claim 2, wherein said porous membrane is impregnated with at least one agent, selected from the group consisting of chemokines, growth factors, pharmaceuticals, co-factors, and functional micro- or nanoparticles. ### Claim 6 (depends on 1) The endovascular stent graft of claim 1, wherein said hydrogel is a composition, comprising a polymer including a three-dimensional network of crosslinked polymer chains, wherein the main chains of said three-dimensional network are composed of poly(ethylene glycol) methyl ether methacrylate (PEGMEMA) polymer chains having the general formula (I) wherein R1 is H or a linear or branched, substituted or unsubstituted alkyl group; R2 is a linear or branched, substituted or unsubstituted alkyl group or a functional group; and n is an integer of from about 6 to about 45; and said main chains are crosslinked by at least an acrylate-based crosslinker comprising an internal disulfide moiety. ### Claim 7 (depends on 6) The endovascular stent graft of claim 6, wherein said main chains are crosslinked by (i) said acrylate-based crosslinker comprising an internal disulfide moiety, and (ii) a poly(ethylene glycol) diacrylate (PEGDA) crosslinker of the general formula (II) wherein n is an integer of from about 16 to about 400. ### Claim 8 (depends on 6) The endovascular stent graft of claim 6, wherein said acrylate-based crosslinker comprising an internal disulfide moiety has the following formula (III): wherein X is selected from NH and O; and R is selected from CH3 and H. ### Claim 9 (depends on 8) The endovascular stent graft of claim 8, wherein said acrylate-based crosslinker comprising an internal disulfide moiety has the following formula (IV) or (V): ### Claim 10 (depends on 6) The endovascular stent graft of claim 6, wherein R1 in formula (I) is methyl. ### Claim 11 (depends on 6) The endovascular stent graft of claim 6, wherein said acrylate-based crosslinker comprising an internal disulfide moiety is present in an amount of at least about 10 mol-%, based on the hydrogel composition. ### Claim 12 (depends on 6) The endovascular stent graft of claim 6, further comprising at least one agent, selected from the group consisting of chemokines, growth factors, pharmaceuticals, co-factors, and functional micro- or nanoparticles. ### Claim 13 (depends on 1) A method for the repair of an aneurysm in a subject, comprising the step of implanting the endovascular stent graft of claim 1 into the affected vascular region of the subject. ### Claim 14 (depends on 13) The method of claim 13, wherein the aneurysm is an aortic aneurysm. ### Claim 15 (depends on 14) The method of claim 14, wherein the aortic aneurysm is a thoracic or thoracoabdominal aortic aneurysm. ### Claim 16 (depends on 1) A method for the prevention of ischemic neurological damage in a subject that is to receive an endovascular stent graft for the treatment of an aneurysm, comprising the step of implanting the endovascular stent graft of claim 1 into the affected vascular region of the subject to treat said aneurysm. ### Claim 17 (depends on 16) The method of claim 16, wherein the aneurysm is an aortic aneurysm. ### Claim 18 (depends on 17) The method of claim 17, wherein the aortic aneurysm is a thoracic or thoracoabdominal aortic aneurysm. ### Claim 19 (depends on 16) The method of claim 16, wherein the ischemic neurological damage is ischemic damage of the spinal cord. ### Claim 20 (depends on 19) The method of claim 19, wherein the ischemic damage of the spinal cord is paraplegia. ### Claim 21 A tubular shunt, wherein the inner walls of said shunt are coated at least partially with hydrogel capable of retarded swelling upon implantation in a subject and thereby reducing the diameter of said tubular shunt or closing said tubular shunt, wherein the retarded swelling occurs over a time course of one to four weeks. ### Claim 22 (depends on 21) The tubular shunt of claim 21, wherein said shunt is a temporary Blalock-Taussig shunt. ### Claim 23 An endovascular stent graft comprising an area having one or more through holes coated at least partially with a hydrogel capable of retarded reduction of the diameter of or retarded occlusion of said through holes by swelling upon implantation in a subject wherein said hydrogel comprises a polymer including a three-dimensional network of crosslinked polymer chains comprised of poly(ethylene glycol) methyl ether methacrylate (PEGMEMA) polymer chains having the general formula (I) wherein R1 is H or a linear or branched, substituted or unsubstituted alkyl group; R2 is a linear or branched, substituted or unsubstituted alkyl group or a functional group; and n is an integer of from about 6 to about 45; and said PEGMEMA polymer chains are crosslinked by at least an acrylate-based crosslinker comprising an internal disulfide moiety.